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very usable manual for the evaluation, treatment options, 
and outcomes of stroke and stroke-related disorders. 
Andrew Gentile, MD 
University of Arizona Health Science Center 
Tucson, Ariz. 
Cerebrovascular disease in clinical practice 
David Wiebers, Valery Feigin, and Robert Brown; Bos- 
ton; 1997; Little, Brown, and Co.; 526 pages; $99.95. 
During the latter part of this century, numerous ad- 
vances have been made in the management of patients with 
cerebrovascular disease. Most resulted from a better under- 
standing of the pathophysiologic mechanisms and clinical 
picture of the various types of disorders, development of 
safer and more accurate diagnostic tools, and improved 
medical and surgical treatment. 
Cerebrovascular disease in clinical practice, by Wiebers, 
Feigin, and Brown, neurologists at the Mayo Clinic in 
Rochester, Minn., offers an updated learning resource and 
quick reference manual designed to advance the compre- 
hensive care of patients. This well-written text provides a 
wealth of useful material that, for the most part, deals with 
clinical assessment of patients with stroke. The six clinical 
management algorithms are one of the highlights and 
should prove helpful to all clinicians. Also, chapters de- 
voted to identification of risk factors and modifications of 
lifestyle are particularly interesting and informative because 
they reflect the current trend of shifting emphasis from 
treatment to prevention of underlying disease and stroke. 
It is important to be mindful, however, that facilities of 
the Mayo Clinic cannot be duplicated by most hospitals, 
especially those in a community setting. Hence, I feel that 
the authors could have provided an even greater service by 
mentioning certain basic facts, for example, results ofnon- 
invasive testing may vary greatly among different laborato- 
ries; some of the more sophisticated studies (OPG, MRA, 
transcranial Doppler) advocated for evaluation of certain 
disorders are not always available in community hospitals. 
Although the authors state that telephone interviews 
are less optimal diagnostically than examination i an office 
or emergency room, I am troubled by the section dealing 
with malting triage decisions on the basis of such inter- 
views. Because an inappropriate decision could result in 
disastrous circumstances for the patient and a possible 
medicolegal problem for the physician, this method of 
handling triage probably should be avoided whenever pos- 
sible or at the very least approached with great circum- 
spect. 
Notwithstanding the above concerns, I consider Cere- 
brovascular Disease in Clinical Practice a valuable addition 
to the literature and recommend the book to all clinicians 
as an effective means of updating their knowledge about 
the current management of cerebrovascular disease. 
Daniel Nunn, MD 
University of Florida Health Science Center 
Jacksonville, Fla. 
Ethical issues in drug research: Through a glass 
darkly 
M. J. Parnham, Amsterdam, 1996, IOS Press, 155 
pages. 
The book Ethical issues in drug research, authored by 
Michael J. Parnham, isa well-written, concise, and easy-to- 
read text on ethical concerns relating to the development 
of pharmaceutical agents. The stimulus for the book was 
the extreme attitude promulgated by some individuals de- 
nouncing the ethical conduct of medical research. These 
attitudes, however, are not completely ill-founded; the 
actions of scientists and business people within the drug 
industry has, on occasion, been less than exemplary. 
Through an ethical appraisal of relevant issues, the 
author seeks to provide a "common ground" on which to 
guide drug development. The book is written with the 
premise that this common ground is best defined by the 
religious and philosophical principles of contemporary 
western society. As such, the text is replete with biblical 
references--even the title of the work was inspired by a 
verse from 1 Corinthians: "For now we see through aglass, 
darkly; but then face to face: now I know in part; but then 
shall I know even as also I am l~nown." 
Ethical issues of drug testing arise solely as a conse- 
quence of the balance between therapeutic response and 
toxicity. The development of "toxicity-free" drugs is de- 
void of ethical concerns. Nutrient drugs are a prime exam- 
ple of such agents; supplementation f sailor's diets of the 
early 1800s with citrus fruits high in vitamin C prevented 
scurvy. More recently, adiet high in polyunsaturated fatty 
acids has been encouraged as being beneficial to the car- 
diovascular system. Neither of these examples was subject 
to major ethical criticism. The author aptly discusses the 
distinction between a nutrient and a drug. Nutrients are 
those molecules required by all, individuals. Only a mini- 
real concentration, well below the threshold level of toxic- 
ity, is necessary for good health. Drugs, by contrast, are 
substances that are not required by healthy individuals. 
Although there is overlap between nutrients and drugs, 
especially when an industrial process concentrates nutrients 
to administer them at supernormal levels, the threshold 
concentrations for efficacy and toxicity are much wider for 
nutrients than for drugs, conferring asubstantial degree of 
safety. This principle was understood as early as five centu- 
ries ago, demonstrated bya quote from the Swiss practitio- 
ner Paracelsus (1493-1541): "All things are poisons, and 
nothing is without poisonous effect; the dose is what makes 
anything poisonous or not." 
Parnham outlines the three common methods of get- 
ting a drug to market: modification of a well-known and 
widely used compound, imitation of a compound evel- 
oped by another company, or de novo development of a 
completely new compound. Although the former two 
methods are quickest and easiest, most current drug devel- 
opment programs involve the latter pathway. An empirical 
approach to drug discovery is h,rgely of historical interest, 
for example, the plant-derived products of the past. Newer 
